ARCHIVES

Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Letter: ORI And Plotkin Should Release Report

June 23, 1995

R01 Grants Pool, New Investigators Hit By Budget Strains

October 27, 1989

Tasigna Wins New Indication For CML; Jevtana Approved For Prostate Cancer

June 18, 2010

DCCR Gets Go Ahead For New Community Clinical Oncology Program, $600,000 – $1 Million a Year

May 12, 1978

Wiernik Loses Post At Einstein Following Unauthorized Trials

November 5, 1993

Ivax Paclitaxel To Remain On Market In Deal With BMS.

February 1, 2002